The MarketReader Minute
💊 Viking Therapeutics Soars on Phase 3 Trial Progress, Gilead Gains on Positive HIV Treatment Data and BioMarin Climbs on FDA Approval | Biotech Sector Insights
Gilead Sciences Inc (GILD) saw a stock price increase after positive data release on Biktarvy at the AIDS 2024 Conference, while Sanofi's strong Q2 earnings and collaboration with Regeneron Pharmaceuticals Inc (REGN) on Dupixent drove REGN's market sentiment positively.